1篇
您的检索式：作者名="Junpei Okamura"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Sofosbuvir plus ribavirin is tolerable and effective even in elderly patients 75-years-old and over显示文摘BACKGROUND Although clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus,patients≥75-years-old have not been included in previous clinical trials.AIM To evaluate the real-world safety and efficacy of sofosbuvir plus ribavirin for elderly patients(≥75-years-old)compared to nonelderly patients,we conducted a post-marketing prospective cohort study.METHODS We treated 265 patients with genotype 2 hepatitis C virus using standard approved doses of sofosbuvir(400 mg/d)plus ribavirin adjusted by body weight,administered orally for 12 wk.RESULTS Sustained virological response rates for the overall cohort,patients<65-years-old,≥65-years-old but<75-years-old,and≥75-years-old were 97%(258/265),98%(93/95),97%(84/87),and 98%(81/83),respectively(P=0.842).Logistic regression analyses identified history of hepatocellular carcinoma treatment and alpha-fetoprotein as factors significantly associated with sustained virological response.Alpha-fetoprotein was the only independent factor identified.Sustained virological response rate was significantly lower for patients with hepatocellular carcinoma treatment(91%)than for patients without history of hepatocellular carcinoma treatment(98%,P=0.004).One patient(0.4%)discontinued treatment due to drug-induced pneumonia.Dose reduction or interruption of ribavirin was required for 12.1%(32/265)of patients because of anemia,including 7.7%(14/182)of patients<75-years-old and 21.7%(18/83)of patients≥75-years-old(P=0.002).CONCLUSION Although ribavirin dose reduction or interruption was required with advanced age,sofosbuvir plus ribavirin appears tolerable and highly effective even in patients≥75-years-old. | Hideyuki Tamai Naoki Shingaki Yoshiyuki Ida Ryo Shimizu Shuya Maeshima Junpei Okamura Akira Kawashima Taisei Nakao Takeshi Hara Hiroyoshi Matsutani Izumi Nishikawa Katsuhiko Higashi | 2020 | World Journal of Hepatology2020，12，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员